Details

Autor(en) / Beteiligte

• Kaiko, Robert F.
• Grandy, Robert P.
• Oshlack, Benjamin
• Pav, Joseph
• Horodniak, Joseph
• Thomas, Gordon
• Ingber, Ellen
• Goldenheim, Paul D.

Titel

The United States experience with oral controlled‐release morphine (MS contin tablets).parts i and ii. review of nine dose titration studies and clinical pharmacology of 15‐mg, 30‐mg, 60‐mg, and 100‐mg tablet strengths in normal subjects

Ist Teil von

• Cancer, 1989-06, Vol.63 (11), p.2348-2354

Ort / Verlag

New York: Wiley Subscription Services, Inc., A Wiley Company

Erscheinungsjahr

1989

Quelle

MEDLINE

Beschreibungen/Notizen

• The results of nine US multicenter, sequential crossover, dose titration studies of controlled‐release oral morphine (MS Contin 30 mg tablets [MSC], Purdue Frederick, Norwalk, CT) are reviewed in Part I. The studies demonstrated the prolonged analgesic efficacy of the preparation in the treatment of patients with moderate to severe cancer‐related pain. Approximately 93% of the patients achieved satisfactory to excellent analgesia on a 12‐hour regimen when appropriate dose titration was allowed. The remaining patients were successfully maintained on an 8‐hour regimen. The preparation was well‐tolerated and comparable in safety to immediate‐release oral morphine. In global evaluations, MSC was judged to be significantly (P < 0.05) more effective, and with significantly (P < 0.05) fewer side effects than both the prestudy opioid analgesics and 4‐hour immediate‐release oral morphine. Patients had a broad range of morphine requirements (mean daily MSC dose, 240 mg; range, 60 mg/day to 1800 mg/day); therefore various MSC tablet strengths were developed. Part II presents three studies in which the MSC formulations (15‐mg, 60‐mg, and 100‐mg tablets) were compared to the 30‐mg tablet within three randomized, single‐dose, two‐way crossover, analytically blinded bioavailability protocols, to determine bioequivalence and dose proportionality. The maximum morphine concentration, time of maximum morphine concentration, and area under the plasma morphine versus 12‐hour and 24‐hour time curve (AUC 0,12; AUC 0,24) were determined in each study. There were no significant differences between the values associated with MSC 1 × 30 mg tablet and 2 × 15 mg tablets (study 1), MSC 2 × 30 mg tablets and 1 × 60 mg tablet (study 2), and MSC 3 × 30 mg tablets and 1 × 100 mg tablet (study 3, values adjusted to dose of 90 mg), except for one marginally significant difference in study 3 (AUC 0,24; P = 0.04) which was not clinically or biopharmaceutically significant. The results showed that MSC 15‐mg, 30‐mg, 60‐mg, and 100‐mg dosage strengths are bioequivalent and dose proportional, and, therefore, therapeutically interchangeable. It was concluded that with routine assessment of the patient and adherence to the principles of analgesic dosing, MSC can be successfully used to control cancer‐related pain. Furthermore, the availability of various MSC tablet strengths can be expected to facilitate the analgesic management of a patient population with widely differing opioid requirements.